BI 3034701 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight (clinicaltrials.gov) - P2 | N=342 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Obesity

A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Boehringer Ingelheim | N=35 ➔ 70 | Trial completion date: Jan 2027 ➔ Jun 2027 | Trial primary completion date: Jan 2027 ➔ Jun 2027

Enrollment change • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=35 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Genetic Disorders • Obesity

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Obesity

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development (GlobeNewswire) - "The Phase II study is designed to evaluate the molecule in people living with obesity and overweight, including dose finding and broader clinical evaluation of efficacy and safety."

New P2 trial • Obesity

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Genetic Disorders • Obesity

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • Genetic Disorders • Obesity

An investigational, potential first-in-class triple GLP-1, GIP, NPY2 receptor agonist peptide (BI 3034701)…will be entering Phase II in the middle of 2026 (Boehringer Ingelheim Press Release)

Pipeline update • Obesity

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development (Boehringer Ingelheim Press Release) - "Progression follows the completion of a randomized, placebo‑controlled Phase I study in healthy volunteers and people with overweight/obesity, where BI 3034701 demonstrated a favorable safety and tolerability profile and showed encouraging weight‑loss."

P1 data • Obesity

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=125 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity (clinicaltrials.gov) - P1 | N=125 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity